4.29
price down icon0.46%   -0.02
 
loading
Schlusskurs vom Vortag:
$4.31
Offen:
$4.24
24-Stunden-Volumen:
382
Relative Volume:
0.03
Marktkapitalisierung:
$211.60M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-5.8439
EPS:
-0.7341
Netto-Cashflow:
-
1W Leistung:
-5.40%
1M Leistung:
-27.84%
6M Leistung:
+4.63%
1J Leistung:
+34.48%
1-Tages-Spanne:
Value
$4.24
$4.24
1-Wochen-Bereich:
Value
$4.24
$4.59
52-Wochen-Spanne:
Value
$3.08
$6.4229

Genfit Adr Stock (GNFT) Company Profile

Name
Firmenname
Genfit Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
167
Name
Twitter
@genfit_pharma
Name
Nächster Verdiensttermin
2024-09-19
Name
Neueste SEC-Einreichungen
Name
GNFT's Discussions on Twitter

Vergleichen Sie GNFT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
GNFT 4.24 211.60M 0 0 0 -0.7341
VRTX 450.19 115.43B 10.63B -479.80M -1.35B 13.33
REGN 746.43 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 592.38 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.25 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.35 24.89B 3.30B -501.07M 1.03B 11.54

Genfit Adr Stock (GNFT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-12-20 Hochstufung H.C. Wainwright Neutral → Buy
2020-07-23 Hochstufung Stifel Hold → Buy
2020-06-25 Eingeleitet BofA/Merrill Underperform
2020-05-13 Herabstufung Kepler Buy → Reduce
2020-05-12 Herabstufung Barclays Overweight → Equal Weight
2020-05-12 Herabstufung H.C. Wainwright Buy → Neutral
2019-10-29 Bestätigt B. Riley FBR Buy
2019-06-25 Eingeleitet Stifel Hold
2019-04-24 Eingeleitet SVB Leerink Outperform
2019-04-22 Eingeleitet Barclays Overweight
Alle ansehen

Genfit Adr Aktie (GNFT) Neueste Nachrichten

pulisher
Nov 15, 2024

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus - GlobeNewswire Inc.

Nov 15, 2024
pulisher
Oct 09, 2024

European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher - MSN

Oct 09, 2024
pulisher
Oct 09, 2024

European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading - MSN

Oct 09, 2024
pulisher
Sep 29, 2024

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading - MSN

Sep 29, 2024
pulisher
Sep 26, 2024

European Equities Traded in the US as American Depositary Receipts Move Higher in Tuesday Trading - MSN

Sep 26, 2024
pulisher
Sep 21, 2024

European Equities Traded in the US as American Depositary Receipts Decrease Friday - MSN

Sep 21, 2024
pulisher
Sep 19, 2024

European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN

Sep 19, 2024
pulisher
Sep 13, 2024

European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - MSN

Sep 13, 2024
pulisher
Sep 08, 2024

European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading - MSN

Sep 08, 2024
pulisher
Sep 06, 2024

European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading - MSN

Sep 06, 2024
pulisher
Sep 06, 2024

European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - MSN

Sep 06, 2024
pulisher
Aug 30, 2024

European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN

Aug 30, 2024
pulisher
Aug 21, 2024

European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher in Wednesday Trading - MSN

Aug 21, 2024
pulisher
Jul 22, 2024

European Equities Traded in the US as American Depositary Receipts Open Week Sharply Higher in Monday Trading - MSN

Jul 22, 2024
pulisher
Jul 09, 2024

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - GlobeNewswire Inc.

Jul 09, 2024
pulisher
Jul 02, 2024

European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading - MSN

Jul 02, 2024
pulisher
Jun 28, 2024

European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading - MSN

Jun 28, 2024
pulisher
Jun 18, 2024

Genfit: New EASL-EASD-EASO guidelines include NIS2+TipRanks.com - TipRanks

Jun 18, 2024
pulisher
Jun 18, 2024

European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading - MSN

Jun 18, 2024
pulisher
Jun 14, 2024

European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading - MSN

Jun 14, 2024
pulisher
Jun 10, 2024

GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary ... - GlobeNewswire

Jun 10, 2024
pulisher
Jun 10, 2024

GENFIT: Historic Milestone Achieved with U.S. FDA - GlobeNewswire

Jun 10, 2024
pulisher
Jun 05, 2024

Home / Today's Market - InvestorPlace

Jun 05, 2024
pulisher
Jun 03, 2024

European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - MSN

Jun 03, 2024
pulisher
Jun 01, 2024

Is Genfit (GNFT) Stock a Solid Choice Right Now - Yahoo Movies UK

Jun 01, 2024
pulisher
May 31, 2024

European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading - MSN

May 31, 2024
pulisher
May 30, 2024

European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading - MSN

May 30, 2024
pulisher
May 22, 2024

European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading - MSN

May 22, 2024
pulisher
May 18, 2024

European Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday Trading - MSN

May 18, 2024
pulisher
Nov 20, 2023

European Equities Traded in the US as American Depositary Receipts Start Week Higher - MSN

Nov 20, 2023
pulisher
Nov 13, 2023

Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine - Ipsen

Nov 13, 2023
pulisher
Jun 30, 2023

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Ipsen

Jun 30, 2023
pulisher
Apr 14, 2022

All You Need to Know About Flex (FLEX) Rating Upgrade to Strong Buy - Zacks Investment Research

Apr 14, 2022
pulisher
Jan 11, 2022

Can GENFIT S.A. Unsponsored ADR (GNFT) Climb 79% to Reach the Level Wall Street Analysts Expect? - Yahoo New Zealand News

Jan 11, 2022
pulisher
Dec 18, 2021

Ipsen und GENFIT schließen im Rahmen einer langfristigen globalen Partnerschaft eine exklusive Lizenzvereinbarung für Elafibranor ab, ein Phase-III-Asset, das für die Behandlung von primärer biliärer Cholangitis geprüft wird - Business Wire

Dec 18, 2021
pulisher
Dec 17, 2021

GENFIT: Ipsen and GENFIT enter into exclusive licensing - GlobeNewswire

Dec 17, 2021
pulisher
Aug 28, 2020

Intercept (ICPT) Posts New Positive Results on NASH Drug - Yahoo Movies UK

Aug 28, 2020
pulisher
May 26, 2020

Intercept Down on Postponement of AdCom Meet for NASH Drug - Yahoo Movies UK

May 26, 2020
pulisher
Mar 17, 2020

The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Sh - Benzinga

Mar 17, 2020
pulisher
Jun 27, 2019

The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO - Yahoo Finance

Jun 27, 2019
pulisher
Jun 12, 2019

The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana - Yahoo Finance

Jun 12, 2019
pulisher
Apr 22, 2019

Genfit (GNFT) Stock Price, News & AnalysisNASDAQ - MarketBeat

Apr 22, 2019
pulisher
Apr 09, 2019

The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing - Yahoo Finance

Apr 09, 2019

Finanzdaten der Genfit Adr-Aktie (GNFT)

Es liegen keine Finanzdaten für Genfit Adr (GNFT) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):